Patrick Amstutz
Net worth: 3 M $ as of 30/06/2026
Net worth: 3 M $ as of 30/06/2026
Patrick Amstutz is the founder of Molecular Partners AG, founded in 2004, holding the title of Chief Executive Officer & Director since 2017.
Dr. Amstutz currently holds the positions of Chief Executive Officer & Director at Molecular Partners, Inc. and President at the Swiss Biotech Association since 2022.
Dr. Amstutz completed a doctorate at the University of Zurich and a graduate degree at the Swiss Federal Institute of Technology.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 31/12/2025 | 7,59,913 ( 1.88% ) | 3 M $ | 30/06/2026 |
| Companies | Position | Start |
|---|---|---|
| MOLECULAR PARTNERS AG | Founder | 22/11/2004 |
Swiss Biotech Association
Swiss Biotech Association Miscellaneous Commercial ServicesCommercial Services Operates as an industry association | President | 03/05/2022 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Chief Executive Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
University of Zurich
University of Zurich Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Swiss Federal Institute of Technology
Swiss Federal Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Molecular Partners AG
Molecular Partners AG BiotechnologyHealth Technology Engages in discovery, development and commercialization of biopharmaceutical products | Health Technology |
Swiss Biotech Association
Swiss Biotech Association Miscellaneous Commercial ServicesCommercial Services Operates as an industry association | Commercial Services |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Select your edition
All financial news and data tailored to specific country editions